It’s no secret that one of the biggest issues in stroke care is the timely arrival of patients to the hospital. The one FDA-indicated drug available for acute ischemic stroke, IV-tPA, must be used within three hours of stroke onset according to FDA indications. The American Stroke Association, however, updated guidelines in 2009 to extend that window to 4.5 hours. By either treatment window, however, few patients are coming into the hospital to receive tPA.
Little progress seen in arrival times for ischemic stroke
This week’s Heart Rhythm Society (HRS) 33rd Annual Scientific Sessions, held in Boston, highlight new innovations in cardiac rhythm management (CRM). Noteworthy research abstracts and late-breaking clinical trials include presentations on sleep disorders and the subcutaneous implantable cardioverter-defibrillator (S-ICD), recently reviewed by an FDA panel. Of particular note was the featured abstract “Remote Monitoring Reduces Healthcare Utilization and Improves Quality of Care in Heart Failure Patients with Implantable Defibrillators: the EVOLVO study.”
HRS 2012: EVOLVO Study Sheds More Light on Remote Monitoring Benefits in EP Device Patients
On March 14th, Mevion Medical Systems (formerly known as Still River Systems) announced the receipt of the European CE Mark for the Mevion S250 system.
Mevion s250 receives CE mark